Erratum: Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/ Metastatic Solid Tumors or Lymphomas (Clin Cancer Res (2022) 28 (677–688) DOI: 10.1158/1078-0432.CCR-21-1963)

Funda Meric-Bernstam, Randy F. Sweis, F. Stephen Hodi, Wells A. Messersmith, Robert H.I. Andtbacka, Matthew Ingham, Nancy Lewis, Xinhui Chen, Marc Pelletier, Xueying Chen, Jincheng Wu, Thomas W. Dubensky, Sarah M. McWhirter, Thomas Müller, Nitya Nair, Jason J. Luke

Research output: Contribution to journal › Comment/debate › peer-review

Fingerprint

Dive into the research topics of 'Erratum: Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/ Metastatic Solid Tumors or Lymphomas (Clin Cancer Res (2022) 28 (677–688) DOI: 10.1158/1078-0432.CCR-21-1963)'. Together they form a unique fingerprint.

Medicine & Life Sciences